|NYSE: GLS||Healthcare / Biotechnology / USA|
|0.1627||-0.0078||-4.57%||Vol 321.47K||1Y Perf -96.24%|
|Mar 31st, 2023 16:00 DELAYED|
|- -||0.00 -1.35%|
|Target Price||1.15||Analyst Rating||Hold 3.00|
|Potential %||606.82||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||★ 41.86|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||0.90||Earnings Rating||—|
|Market Cap||11.93M||Earnings Date||11th May 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||11th May 2023|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||450.58K|
|Avg. Monthly Volume||647.91K|
|Avg. Quarterly Volume||384.80K|
Gelesis Holdings Inc. (NYSE: GLS) stock closed at 0.1627 per share at the end of the most recent trading day (a -4.57% change compared to the prior day closing price) with a volume of 321.47K shares and market capitalization of 11.93M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Gelesis Holdings Inc. CEO is Yishai Zohar.
The one-year performance of Gelesis Holdings Inc. stock is -96.24%, while year-to-date (YTD) performance is -43.97%. GLS stock has a five-year performance of %. Its 52-week range is between 0.11 and 5.95, which gives GLS stock a 52-week price range ratio of 0.90%
Gelesis Holdings Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 5.23, a price-to-sale (PS) ratio of 1.26, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.35%, a ROC of -169.41% and a ROE of 1 247.07%. The company’s profit margin is -%, its EBITDA margin is -121.20%, and its revenue ttm is $23.14 Million , which makes it $0.32 revenue per share.
Of the last four earnings reports from Gelesis Holdings Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Gelesis Holdings Inc.’s next earnings report date is 11th May 2023.
The consensus rating of Wall Street analysts for Gelesis Holdings Inc. is Hold (3), with a target price of $1.15, which is +606.82% compared to the current price. The earnings rating for Gelesis Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Gelesis Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Gelesis Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.10, ATR14 : 0.05, CCI20 : -68.74, Chaikin Money Flow : 0.02, MACD : -0.03, Money Flow Index : 74.25, ROC : -17.62, RSI : 40.44, STOCH (14,3) : 29.74, STOCH RSI : 0.08, UO : 56.51, Williams %R : -70.26), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Gelesis Holdings Inc. in the last 12-months were: Raju S. Kucherlapati (Buy at a value of $92 467)
|Analyst Ratings||Current||1 M ago||3 M ago|
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
CEO: Yishai Zohar
Telephone: +1 512 340-7800
Address: 405 West 14th Street, Austin 78701, TX, US
Number of employees: 0
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.